Tumor Biology

, Volume 36, Issue 12, pp 9703–9709 | Cite as

MicroRNA 211 expression is upregulated and associated with poor prognosis in colorectal cancer: a case–control study

  • Ahmet Taner Sümbül
  • Bülent Göğebakan
  • Süleyman Bayram
  • Celal Yücel Batmacı
  • Serdar Öztuzcu
Research Article

Abstract

Increasingly more evidence support the role of the microRNAs (miRNA) in tumorigenesis. The role of up/downregulation microRNA-211 (miR-211) during human tumorigenesis is still contentious and may exhibit tissue-specific regulatory manner, but the exhaustive mechanisms underlying its pro/anti-oncogenic effects remain to be unknown. Sixty-six patients that were diagnosed and operated with colorectal cancer (CRC) and sixty-five healthy cases that were age and sex compatible with them were included in our study. miRNA was isolated from the formalin-fixed paraffin-embedded (FFPE) tissues of all cases. The expression level of miR-211 in matched normal and tumor tissues of CRC group and healthy group was evaluated using a quantitative real-time RT-PCR (qRT-PCR). Based on the average miR-211 levels, two groups of low or high expression were formed in CRC group. Correlation of the patients’ clinicopathological factors and survival was also analyzed. No statistically significant differences were found in miR-211 levels among tumorous and normal tissues of CRC patient group (P = 0.59). Also, no statistically significant correlation was determined between clinicopathological factors and miR-211 expression level in CRC group. However, miR-211 expression levels between the CRC group and the healthy group were determined to be of statistical significance (P < 0.0001). There were 33 (50 %) CRC patients that expressed low levels of miR-211 and 33 (50 %) CRC patients that expressed high levels of miR-211. A median survival between low levels of miR-211 group and high levels of miR-211 group was evaluated via Kaplan–Meier, and the difference was of statistical significance (P = 0.035). The univariate analysis of the factors that may affect survival indicated invasion depth (P = 0.063), lymphovascular invasion (P = 0.011), perineural invasion (P = 0.009), and miR-211 expression level (P = 0.041) presence to be effective. In the multivariate analysis of these factors with overall survival, only miR-211 expression level (P = 0.01) was effective on overall survival. Our results suggest for the first time that miR-211 expressed more in CRC patients than in healthy group could be a new prognostic biomarker in order to predict survival. Independent studies are needed to validate our findings in a larger series, as well as in cancer of different tissues.

Keywords

Colorectal cancer microRNA miR-211 Biomarker 

Notes

Acknowledgments

This study was performed with a grant taken from the Turkish Medical Oncology Society.

Conflicts of interest

None

References

  1. 1.
    Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014. doi: 10.1002/ijc.29210.PubMedGoogle Scholar
  2. 2.
    Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C, et al. Identification and expansion of human colon-cancer-initiating cells. Nature. 2007;445(7123):111–5.CrossRefPubMedGoogle Scholar
  3. 3.
    Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao X, et al. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2013;6(12):2904–11.PubMedPubMedCentralGoogle Scholar
  4. 4.
    Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281–97.CrossRefPubMedGoogle Scholar
  5. 5.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMedGoogle Scholar
  6. 6.
    Waldman SA, Terzic A. Translating MicroRNA discovery into clinical biomarkers in cancer. JAMA. 2007;297(17):1923–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Esquela-Kerscher A, Slack FJ. Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259–69.CrossRefPubMedGoogle Scholar
  8. 8.
    Sümbül AT, Göğebakan B, Ergün S, Yengil E, Batmacı CY, Tonyalı O, et al. miR-204-5p expression in colorectal cancer: an autophagy-associated gene. Tumour Biol. 2014. doi: 10.1007/s13277-014-2596-3.PubMedGoogle Scholar
  9. 9.
    Huang Z, Huang D, Ni S, Peng Z, Sheng W, Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer. 2010;127(1):118–26.CrossRefPubMedGoogle Scholar
  10. 10.
    Chang KW, Liu CJ, Chu TH, Cheng HW, Hung PS, Hu WY, et al. Association between high miR-211 microRNA expression and the poor prognosis of oral carcinoma. J Dent Res. 2008;87(11):1063–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Cai C, Ashktorab H, Pang X, Zhao Y, Sha W, Liu Y, et al. MicroRNA-211 expression promotes colorectal cancer cell growth in vitro and in vivo by targeting tumor suppressor CHD5. PLoS One. 2012;7(1), e29750.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Chu TH, Yang CC, Liu CJ, Lui MT, Lin SC, Chang KW. miR-211 promotes the progression of head and neck carcinomas by targeting TGFβRII. Cancer Lett. 2013;337(1):115–24.CrossRefPubMedGoogle Scholar
  13. 13.
    Levy C, Khaled M, Iliopoulos D, Janas MM, Schubert S, Pinner S, et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell. 2010;40(5):841–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Mazar J, DeYoung K, Khaitan D, Meister E, Almodovar A, Goydos J, et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One. 2010;5(11), e13779.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Sakurai E, Maesawa C, Shibazaki M, Yasuhira S, Oikawa H, Sato M, et al. Downregulation of microRNA-211 is involved in expression of preferentially expressed antigen of melanoma in melanoma cells. Int J Oncol. 2011;39(3):665–72.PubMedGoogle Scholar
  16. 16.
    Boyle GM, Woods SL, Bonazzi VF, Stark MS, Hacker E, Aoude LG, et al. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res. 2011;24(3):525–37.CrossRefPubMedGoogle Scholar
  17. 17.
    Xu Y, Brenn T, Brown ER, Doherty V, Melton DW. Differential expression of microRNAs during melanoma progression: miR-200c, miR-205 and miR-211 are downregulated in melanoma and act as tumour suppressors. Br J Cancer. 2012;106(3):553–61.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Giovannetti E, van der Velde A, Funel N, Vasile E, Perrone V, Leon LG, et al. High-throughput microRNA (miRNAs) arrays unravel the prognostic role of MiR-211 in pancreatic cancer. PLoS One. 2012;7(11), e49145.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Maftouh M, Avan A, Funel N, Frampton AE, Fiuji H, Pelliccioni S, et al. miR-211 modulates gemcitabine activity through downregulation of ribonucleotide reductase and inhibits the invasive behavior of pancreatic cancer cells. Nucleosides Nucleotides Nucleic Acids. 2014;33(4–6):384–93.CrossRefPubMedGoogle Scholar
  20. 20.
    Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a evelopmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003;113(1):25–36.CrossRefPubMedGoogle Scholar
  21. 21.
    Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, Macdonald PE, et al. A pancreatic islet-specific microRNA regulates insulin secretion. Nature. 2004;432(7014):226–30.CrossRefPubMedGoogle Scholar
  22. 22.
    Thai TH, Calado DP, Casola S, Ansel KM, Xiao C, Xue Y, et al. Regulation of the germinal center response by microRNA-155. Science. 2007;316(5824):604–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Ventura A, Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell. 2009;136:586–91.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Liu H, Du L, Wen Z, Yang Y, Li J, Wang L, et al. Up-regulation of miR-182 expression in colorectal cancer tissues and its prognostic value. Int J Colorectal Dis. 2013;28(5):697–703.CrossRefPubMedGoogle Scholar
  25. 25.
    Zhang G, Xia S, Tian H, Liu Z, Zhou T. Clinical significance of miR-22 expression in patients with colorectal cancer. Med Oncol. 2012;29(5):3108–12.CrossRefPubMedGoogle Scholar
  26. 26.
    Wang CJ, Zhou ZG, Wang L, Yang L, Zhou B, Gu J, et al. Clinicopathological significance of microRNA-31, −143 and −145 expression in colorectal cancer. Dis Markers. 2009;26(1):27–34.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Zhou T, Zhang G, Liu Z, Xia S, Tian H. Overexpression of miR-92a correlates with tumor metastasis and poor prognosis in patients with colorectal cancer. Int J Colorectal Dis. 2013;28(1):19–24.CrossRefPubMedGoogle Scholar
  28. 28.
    Zhou T, Zhang GJ, Zhou H, Xiao HX, Li Y. Overexpression of microRNA-183 in human colorectal cancer and its clinical significance. Eur J Gastroenterol Hepatol. 2014;26(2):229–33.CrossRefPubMedGoogle Scholar
  29. 29.
    Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Yu H, Gao G, Jiang L, Guo L, Lin M, Jiao X, et al. Decreased expression of miR-218 is associated with poor prognosis in patients with colorectal cancer. Int J Clin Exp Pathol. 2013;6(12):2904–11.PubMedPubMedCentralGoogle Scholar
  31. 31.
    Sarver AL, Li L, Subramanian S. MicroRNA miR-183 functions as an oncogene by targeting the transcription factor EGR1 and promoting tumor cell migration. Cancer Res. 2010;70:9570–80.CrossRefPubMedGoogle Scholar
  32. 32.
    Wang X, Wang J, Ma H, Zhang J, Zhou X. Downregulation of miR-195 correlates with lymph node metastasis and poor prognosis in colorectal cancer. Med Oncol. 2012;29(2):919–27.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Ahmet Taner Sümbül
    • 1
  • Bülent Göğebakan
    • 2
  • Süleyman Bayram
    • 3
  • Celal Yücel Batmacı
    • 4
  • Serdar Öztuzcu
    • 5
  1. 1.Department of Medical OncologyBaskent UniversityAdanaTurkey
  2. 2.Department of Biology and GeneticsMustafa Kemal UniversityHatayTurkey
  3. 3.Department of Nursing, Adıyaman School of HealthAdıyaman UniversityAdıyamanTurkey
  4. 4.Department of Internal MedicineMustafa Kemal UniversityHatayTurkey
  5. 5.Department of Biology and GeneticsGaziantep UniversityGaziantepTurkey

Personalised recommendations